A new inhaled antibiotic for the treatment of cystic fibrosis called Cayston® is now available for patients through select specialty pharmacies, including the CF Services Pharmacy.
Site Search
A key focus of this year's North American Cystic Fibrosis Conference (NACFC) was the progress of the more than 30 potential new therapies moving through the CF Foundation's drug development pipeline.
PTC Therapeutics has discontinued development of ataluren as a potential treatment for people with cystic fibrosis caused by a nonsense mutation. The Cystic Fibrosis Foundation is supporting efforts to pursue treatments for people with CF who have a nonsense, splicing or other rare mutations.
The Cystic Fibrosis Foundation awarded up to $4.7 million to EnBiotix Inc. to study the potential use of inhaled colistin as an additional option to treat Pseudomonas infections in people with cystic fibrosis who are not responding to current treatments.
The Cystic Fibrosis Foundation awarded up to $3.5 million to Arrevus Inc. to test a potential treatment for pulmonary exacerbations in people with cystic fibrosis in a late phase clinical trial.
Melanie Lawrence, an adult with cystic fibrosis, was selected to testify before a Senate Health, Education, Labor and Pensions subcommittee regarding the impact of antimicrobial resistance on patients who face heightened risk of infections, like those with CF.
A new law that allows patients with rare diseases to participate in clinical trials without losing eligibility for public health care benefits went into effect yesterday. The bill, known as the “Improving Access to Clinical Trials Act” (IACT), was championed by the Cystic Fibrosis Foundation and signed into law in October 2010.
The investment will go toward finishing a Phase 2a clinical trial for an anti-infective to treat chronic infections in people with CF.
Bill will jump-start rebuilding of the antibiotics pipeline that is vital to stave off a looming pandemic.